Markowitz M S
AWHONNS Clin Issues Perinat Womens Health Nurs. 1993;4(4):578-88.
Research using human fetal tissue is well established in biomedical science and indicates promising results in clinical transplantation for some diseases. Because the most optimal tissue for use in transplantation is obtained from fetuses resulting from elective abortions, this technology provokes ethical controversy. Societal concern about the ethical feasibility of human fetal tissue transplantation research (HFTTR) culminates with its investigative use in the treatment of Parkinson's disease. Reflective of such concern in the United States was the 1988 ban on federal funding for HFTTR using tissue obtained from electively terminated abortuses and the establishment of the HFTTR Panel. Considerations generating ethical debate about HFTTR include the moral status of the fetus, who should consent to use of fetal tissue in transplantation research, and issues related to complicity in, and legitimization of, abortion. The moratorium on federal funding for HFTTR has been lifted, but ethical issues and societal concerns remain unresolved.
在生物医学领域，使用人类胎儿组织进行研究已相当成熟，并且在某些疾病的临床移植方面显示出了有前景的成果。由于用于移植的最佳组织是从选择性堕胎产生的胎儿身上获取的，这项技术引发了伦理争议。社会对人类胎儿组织移植研究（HFTTR）伦理可行性的关注，在其用于治疗帕金森病的研究中达到了顶点。美国1988年禁止联邦政府资助使用从选择性终止妊娠的胎儿身上获取组织进行的HFTTR，并设立了HFTTR小组，这反映了这种关注。引发关于HFTTR伦理辩论的因素包括胎儿的道德地位、谁应该同意在移植研究中使用胎儿组织，以及与堕胎同谋和合法化相关的问题。联邦政府对HFTTR资金的暂停资助已经解除，但伦理问题和社会关注仍然没有得到解决。
